Association of clinical features of polycystic ovarian syndrome with body mass index and gonadotropin hormones

Abstract

Background: Diagnosing polycystic ovarian syndrome (PCOS) is utmost important to treat accurately and also to assess further complications, as PCOS has higher rates of endometrial cancer, cardiovascular disease, dyslipidemia, and type 2 diabetes mellitus. Aims and Objectives: The objectives of this study were to know the clinical features of PCOS and to know the association of PCOS with gonadotropin hormones and body mass index (BMI). Materials and Methods: A prospective study conducted on PCOS patients from January 2018 to April 2019. PCOS was diagnosed by clinical, laboratory, and radiological investigations. PCOS patients were advised to undergo gonadotropin hormones analysis. Results: About 50% of patients with oligomenorrhea, acne, hirsutism, and polycystic ovaries had luteinizing hormone/follicular-stimulating hormone (LH/FSH) ratio >2/1. Around 60% of patients with polycystic ovaries had BMI 25. Polycystic ovaries have shown signification in relation to LH/FSH >2/1 (95% confidence interval [CI] 2.05–31.09; P = 0.002), FSH ≥7 (95% CI 0.02–0.40; P = 0.001), and LH ≥10 (95% CI 0.05–0.75; P = 0.001). Conclusion: PCOS diagnosis is a multidisciplinary approach should be evaluated by clinical features, hormonal evaluation, and radiological investigations. Diagnosing polycystic ovaries by ultrasonography and hyperandrogenism are a hallmark for PCOS.